Alette Ortega

Dr. Alette Ortega


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2013 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
LRLuis L Rojas-Puentes
Luis L Rojas-Puentes
MGMarcelino Gonzalez-Pinedo
Marcelino Gonzalez-Pinedo
ACAlejando Crismatt
Alejando Crismatt
AOAlette Ortega
Alette Ortega
CGCarlos Gamboa-Vignolle
Carlos Gamboa-Vignolle
OAOscar Arrieta
Oscar Arrieta
Background and purpose: Chloroquine (CLQ), an antimalarial drug, has a lysosomotropic effect associated with increased radiationsensibility, which is mediated by the leakage of hydrolytic enzymes, increased apoptosis, autophagy and increased oxidative stress in vitro. In this phase II study, we evaluated the efficacy and safety of radiosensibilization using CLQ concomitant with 30 Gray (Gy) of whole-brain irradiation (WBI) to treat patients with brain metastases (BM) from solid tumors. Methods: Seventy-three eligible patients were randomized. Thirty-nine patients received WBI (30 Gy in 10 fractions over 2 weeks) concomitant with 150 mg of CLQ for 4 weeks (the CLQ arm). Thirty-four patients received the same schedule of WBI concomitant with a placebo for 4 weeks (the control arm). All the patients were evaluated for quality of life (QoL) using the EORTC Quality of Life (QoL) Questionnaire (EORTC QLQ-C30) (Mexican version) before beginning radiotherapy and one month later. Results: The overall response rate (ORR) was 54% for the CLQ arm and 55% for the control arm (p=0.92). The progression-free survival of brain metastases (BMPFS) rates at one year were 83.9% (95% CI 69.4-98.4) for the CLQ arm and 55.1% (95% CI 33.6-77.6) for the control arm. Treatment with CLQ was independently associated with increased BMPFS (RR 0.31,95% CI [0.1-0.9], p=0.046).The only factor that was independently associated with increased overall survival (OS) was the presence of< 4 brain metastases (RR 1.9, 95% CI [1.12-3.3], p=0.017). WBI was associated with improvements in cognitive and emotional function but also with worsened nausea in both patients groups. No differences in QoL or toxicity were found between the study arms. Conclusion: Treatment with CLQ plus WBI improved the control of BM (compared with the control arm) with no increase in toxicity; however, CLQ did not improve the RR or OS. A phase III clinical trial is warranted to confirm these findings.

27 June 2018 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
RBRubén Rodríguez Bautista
Rubén Rodríguez Bautista
AOAlette Ortega
Alette Ortega
AHAlfredo Hidalgo-Miranda
Alfredo Hidalgo-Miranda
ADAlejandro Zentella Dehesa
Alejandro Zentella Dehesa
CVCynthia Villarreal-Garza
Cynthia Villarreal-Garza
OAOscar Arrieta
Oscar Arrieta
Triple-negative breast cancer (TNBC) has been clinically difficult to manage because of tumor aggressiveness, cellular and histological heterogeneity, and molecular mechanisms’ complexity. All this in turn leads us to evaluate that tumor biological behavior is not yet fully understood. Additionally, the heterogeneity of tumor cells represents a great biomedicine challenge in terms of the complex molecular—genetical-transcriptional and epigenetical—mechanisms, which have not been fully elucidated on human solid tumors. Recently, human breast cancer, but specifically TNBC is under basic and clinical-oncology research in the discovery of new molecular biomarkers and/or therapeutic targets to improve treatment responses, as well as for seeking algorithms for patient stratification, seeking a positive impact in clinical-oncology outcomes and life quality on breast cancer patients. In this sense, important knowledge is emerging regarding several cancer molecular aberrations, including higher genetic mutational rates, LOH, CNV, chromosomal, and epigenetic alterations, as well as transcriptome aberrations in terms of the total gene-coding ribonucleic acids (RNAs), known as mRNAs, as well as non-coding RNA (ncRNA) sequences. In this regard, novel investigation fields have included microRNAs (miRNAs), as well as long ncRNAs (lncRNAs), which have been importantly related and are likely involved in the induction, promotion, progression, and/or clinical therapeutic response trackers of TNBC. Based on this, in general terms according with the five functional archetype classification, the lncRNAs may be involved in the regulation of several molecular mechanisms which include genetic expression, epigenetic, transcriptional, and/or post-transcriptional mechanisms, which are nowadays not totally understood. Here, we have reviewed the main dis-regulated and functionally non- and well-characterized lncRNAs and their likely involvement, from a molecular enrichment and mechanistic point of view, as tumor biomarkers for breast cancer and its specific histological subtype, TNBC. In reference to the abovementioned, it has been described that some lncRNA expression profiles correspond or are associated with the TNBC histological subtype, potentially granting their use for TNBC malignant progression, diagnosis, tumor clinical stage, and likely therapy. Based on this, lncRNAs have been proposed as potential biomarkers which might represent potential predictive tools in the differentiated breast carcinomas versus TNBC malignant disease. Finally, elucidation of the specific or multi-functional archetypal of lncRNAs in breast cancer and TNBC could be fundamental, as these molecular intermediary-regulator “lncRNAs” are widely involved in the genome expression, epigenome regulation, and transcriptional and post-transcriptional tumor biology, which in turn will probably represent a new prospect in clinical and/or therapeutic molecular targets for the oncological management of breast carcinomas in general and also for TNBC patients.

29 January 2016 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
JGJ. A. Guadarrama-Orozco
J. A. Guadarrama-Orozco
AOAlette Ortega
Alette Ortega
Erika Ruiz-GarciaErika Ruiz-Garcia
Erika Ruiz-Garcia
HVH. Astudillo-De la Vega
H. Astudillo-De la Vega
AMA. Meneses-García
A. Meneses-García
César López-CamarilloCésar López-Camarillo
César López-Camarillo

15 September 2020 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
ATAna Laura Torres-Román
Ana Laura Torres-Román
VGVictor Manuel García-Hernández
Victor Manuel García-Hernández
EREdgar Rangel-López
Edgar Rangel-López
ERErika Ruiz-García
Erika Ruiz-García
AMAbelardo Meneses-García
Abelardo Meneses-García
AOAlette Ortega
Alette Ortega

8 August 2018 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
RBRubén Rodríguez Bautista
Rubén Rodríguez Bautista
AOAlette Ortega
Alette Ortega
AMAlfredo Hidalgo Miranda
Alfredo Hidalgo Miranda
ADAlejandro Zentella Dehesa
Alejandro Zentella Dehesa
CVCynthia Villarreal-Garza
Cynthia Villarreal-Garza
OAOscar Arrieta
Oscar Arrieta
Upon publication of the original article [1], the authors noticed that the Figs. 1, 2 and 3 were incorrectly given.

1 October 2023 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ATAna Laura Torres-Román
Ana Laura Torres-Román
KRKarla Lucero Rodríguez-Flores
Karla Lucero Rodríguez-Flores
VHVíctor Manuel Hernández-Mora
Víctor Manuel Hernández-Mora
ERErika Ruiz-García
Erika Ruiz-García
OPOscar Prospero-García
Oscar Prospero-García
AOAlette Ortega
Alette Ortega
Histaminergic, orexinergic, and cannabinoid systems play a role in both physiologic and oncogenic mechanisms in digestive tissues. These three systems are important mediators of tumor transformation, as they are associated with redox alterations, which are key aspects in oncological disorders. The three systems are known to promote alterations in the gastric epithelium through intracellular signaling pathways, such as oxidative phosphorylation, mitochondrial dysfunction, and increased Akt, which might promote tumorigenesis. Histamine promotes cell transformation through redox-mediated alterations in the cell cycle, DNA repair, and immunological response. The increase in histamine and oxidative stress generates angiogenic and metastatic signals through the VEGF receptor and H2R-cAMP-PKA pathway. Immunosuppression in the presence of histamine and ROS is linked to a decrease in dendritic and myeloid cells in gastric tissue. These effects are counteracted by histamine receptor antagonists, such as cimetidine. Regarding orexins, overexpression of the Orexin 1 Receptor (OX1R) induces tumor regression through the activation of MAPK-dependent caspases and src-tyrosine. OX1R agonists are candidates for the treatment of gastric cancer by stimulating apoptosis and adhesive interactions. Lastly, cannabinoid type 2 (CB2) receptor agonists increase ROS, leading to the activation of apoptotic pathways. In contrast, cannabinoid type 1 (CB1) receptor agonists decrease ROS formation and inflammation in gastric tumors exposed to cisplatin. Overall, the repercussion of ROS modulation through these three systems on tumor activity in gastric cancer depends on intracellular and/or nuclear signals associated with proliferation, metastasis, angiogenesis, and cell death. Here, we review the role of these modulatory systems and redox alterations in gastric cancer.